Benoni Roberto, Panunzi Silvia, Batani Veronica, Moretti Francesca, Fuggini Stefano, Todesco Mattia, Senna Gianenrico, Poli Albino, Vianello Andrea, Caminati Marco
Section of Hygiene, Dept of Diagnostics and Public Health, University of Verona, Verona, Italy.
Unit of Epidemiology and Medical Statistics, Dept of Diagnostics and Public Health, University of Verona, Verona, Italy.
ERJ Open Res. 2022 Jul 18;8(3). doi: 10.1183/23120541.00670-2021. eCollection 2022 Jul.
Whether sex can influence the clinical response to biological treatment in patients with severe asthma has not been fully addressed.
The aim of this study was to investigate in patients with severe asthma undergoing biological treatment the individual evolution of lung function measurements and patient-reported asthma control scores over a 12-month follow-up period, in relation to patients' sex, in different age ranges. Second, the change in the administered dose of oral corticosteroids (OCS) before and after 12 months of treatment was investigated.
64 patients (58% female and 42% male) with a median age of 52 years were enrolled in the study. There were no relevant differences between sexes in terms of lung function, patient-reported asthma control, exacerbation rate and daily OCS dose within the study timeframe. A separate sub-analysis by biological treatment confirmed the same finding. Stratifying individuals by age, we showed that older men had lower lung function parameter values (forced expiratory volume in 1 s (FEV) % predicted and FEV/forced vital capacity index) than older women, whereas an opposite trend was observed in terms of Asthma Control Test score. No other relevant differences were detected after age stratification.
According to our findings, sex does not act as a determinant of treatment response to biologicals in people with severe asthma. Although to be confirmed in larger studies, our data suggest that neither sex nor age should limit biological treatment prescription, once the eligibility criteria for that therapy are satisfied.
性别是否会影响重度哮喘患者对生物治疗的临床反应尚未得到充分研究。
本研究旨在调查接受生物治疗的重度哮喘患者在12个月随访期内,肺功能测量值和患者报告的哮喘控制评分的个体变化情况,以及不同年龄范围内与患者性别的关系。其次,研究治疗12个月前后口服糖皮质激素(OCS)给药剂量的变化。
64例患者(女性占58%,男性占42%)纳入研究,中位年龄为52岁。在研究时间范围内,性别在肺功能、患者报告的哮喘控制、加重率和每日OCS剂量方面无显著差异。按生物治疗进行的单独亚分析证实了相同的结果。按年龄分层后,我们发现老年男性的肺功能参数值(1秒用力呼气容积(FEV)占预计值百分比和FEV/用力肺活量指数)低于老年女性,而在哮喘控制测试评分方面观察到相反趋势。年龄分层后未发现其他显著差异。
根据我们的研究结果,性别并非重度哮喘患者对生物制剂治疗反应的决定因素。尽管有待更大规模研究证实,但我们的数据表明,一旦满足该疗法的纳入标准,性别和年龄均不应限制生物治疗的处方。